Comparison of bivalent and monovalent mRNA vaccine boosters.
Carlos King-Ho WongKristy T K LauIvan C H AuEric H Y LauBenjamin J CowlingPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
In this cohort study conducted in Hong Kong where both bivalent and monovalent formulations of BNT162b2 were available, there was no significant differences in the mortality or hospitalization between those who received bivalent and monovalent mRNA as second boosters. Bivalent and monovalent mRNA boosters appear equally protective against clinical outcomes.